<DOC>
	<DOCNO>NCT01507311</DOCNO>
	<brief_summary>This trial conduct Europe . The aim trial ass effect NNC 90-1170 ( liraglutide ) pulsatile insulin secretion insulin secretion standard meal subject type 2 diabetes .</brief_summary>
	<brief_title>Effect Liraglutide Pulsatile Insulin Secretion Subjects With Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Liraglutide</mesh_term>
	<criteria>Diagnosed type 2 diabetes , either newly diagnose least two month diet treatment , current OHA ( oral hypoglycaemic agent ) treatment stable dose least six month BMI ( Body Mass Index ) 24 35 kg/m^2 ( inclusive ) Fasting plasma glucose 6 15 mmol/l ( inclusive ) AntiGAD ( glutamic acid decarboxylase ) negative Known suspect allergy trial product relate product Receipt investigational drug within three month prior trial Recurrent severe hypoglycaemia judged investigator Cardiac disease clinically significant abnormal ECG ( electrocardiogram ) Use drug ( except oral hypoglycaemic agent ( OHAs ) ) investigator 's opinion could interfere blood glucose level ( i.e. , insulin , systemic corticosteroid , thiazide ) Liver renal disease</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>